Redeye initiates coverage of Fluoguide, a Denmark-based medtech company developing optical probes for fluorescence-guided cancer surgery. The company is about to conclude a phase I/II trial in high-grade glioma and has set its sight on market approval for lead candidate FG001 in 2025. Through label expansion into other, more prevalent cancers, we believe lead candidate FG001 has blockbuster potential.